IPA jetzt rein, hat Luft bis 9 Dollar, tolle Zahle

Gruss E.

http://chart.bigcharts.com/bc3/quickchart/...07&mocktick=1&rand=2825"

Interpharm Announces Record Revenue and Earnings for the Three and Six Month Periods Ended December 31, 2003  
Wednesday, Febuary 4, 2004 08:55 AM ET  Printer-friendly version  
 
COMMACK, N.Y., Feb. 4 /PRNewswire-FirstCall/ -- Interpharm Holdings, Inc. (Amex: IPA, news) today announced its operating results for the three and six-month periods ended December 31, 2003.
   Financial Highlights


                                         Three-Months Ended December 31,
                                               2003               2002
                                            (Unaudited)       (Unaudited)

   Revenue            Increased      76%     $11,706,000       $6,636,000
   Gross Profit       Increased     117%      $2,618,000       $1,204,000
   Operating Income   Increased     286%      $1,586,000         $411,000
   Net Income         Increased     320%      $1,024,000         $244,000


                                           Six-Months Ended December 31,
                                               2003               2002
                                            (Unaudited)        (Unaudited)

   Revenue            Increased      48%     $18,582,000       $12,569,000
   Gross Profit       Increased      77%      $4,050,000        $2,288,000
   Operating Income   Increased     150%      $1,931,000          $773,000
   Net Income         Increased     185%      $1,252,000          $440,000


 


 

 

Gruss E.  

finde den alten Thread nicht wieder, verflucht. Wieviel Luft gönnst Du AELA?

Gruss E.

http://chart.bigcharts.com/bc3/quickchart/...94&mocktick=1&rand=9371"

AEterna through its subsidiary Zentaris signs partnership with Roche in Brazil for new treatment of leishmaniasis, a devastating tropical disease  
MONDAY, FEBRUARY 02, 2004 9:27 AM
- PR Newswire




 AELA
 5.03  +0.85  


QUEBEC CITY (Canada), RIO DE JANEIRO (Brazil), FRANKFURT (Germany), Feb 2, 2004 /PRNewswire-FirstCall via COMTEX/ -- Roche and AEterna Laboratories Inc. (CA:AEL) announced today a partnership for the marketing in Brazil of Impavido(R) (Miltefosine), the breakthrough oral therapy of leishmaniasis. The agreement was signed between Produtos Roche QFSA in Sao Paulo and Zentaris GmbH in Frankfurt, a 100% subsidiary of AEterna Laboratories Inc.

Under this agreement, Roche will support Zentaris in the registration process and will market the product for Zentaris in Brazil. Furthermore, Zentaris will supply Impavido(R) to Roche. Brazil is the country in South America that is most affected with the deadly visceral leishmaniasis (black fever) and the painful cutaneous leishmaniasis (parasitic skin disease). Both parties will immediately start clinical bridging trials, as requested from the Brazilian health authorities.

The registration of the first oral treatment for leishmaniasis in Brazil would be a breakthrough in fighting this awful disease. It is estimated that, every year, up to 50,000 people are newly infected in Brazil, 10% of them with the deadly visceral form. Because of these numbers, there is an urgent need for new treatments for leishmaniasis and Impavido(R) in Brazil.

"The drug has proven to be safe and effective in India for visceral leishmaniasis and in clinical trials for cutaneous leishmaniasis in Colombia and Guatemala," said Prof. Jurgen Engel, Managing Director of Zentaris GmbH, Executive Vice President, Global R&D and Chief Operating Officer at AEterna. "The partnership with Roche is the best opportunity to make the drug available very fast in Brazil where it is urgently needed."

Leishmaniasis is a tropical disease caused by the leishmania parasite. According to the World Health Organization (WHO), more than 12 million people are affected worldwide, with an infection rate of 2 million new cases per year. Impavido(R) has recently been approved in India for the treatment of the visceral form of this disease.


    About Roche


 

Hast schon ma in dein Postfach (Eskivana) gschaut - deswegen witzig.

Also, muss ja mal sagen, ist schon ne komische Krankheit, aber wenn die ihr Zeug an den Mann bekommen und die WHO die empfiehlt, sind die am Ende des Jahres auch bei $1o+x. Aber eben nur wenn. Kann keine Aussage über die Wirksamkeit des Medikamentes treffen.


patzi